Edgewise Therapeutics (EWTX) Assets Average (2021 - 2026)

Edgewise Therapeutics has disclosed Assets Average across 6 years of filings, most recently posting $535.6 million for Q1 2026.

• Assets Average for Q1 2026 came in at $535.6 million, up 13.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $535.6 million (up 13.8% YoY), and the FY2025 annual result was $519.7 million, up 25.71% from the prior year.
• Assets Average came in at $535.6 million for Q1 2026 at Edgewise Therapeutics, down from $568.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $598.4 million in Q3 2025 to a low of $265.1 million in Q2 2022.
• The 5-year median for Assets Average is $446.9 million (2024), against an average of $428.9 million.
• Across the five-year window, Assets Average retreated 13.76% in 2022 and jumped 62.45% in 2024, its largest moves.
• Edgewise Therapeutics' Assets Average stood at $372.1 million in 2022, then slipped by 12.48% to $325.7 million in 2023, then surged by 53.22% to $499.0 million in 2024, then increased by 13.82% to $568.0 million in 2025, then fell by 5.72% to $535.6 million in 2026.
• The last three Assets Average figures came in at $535.6 million (Q1 2026), $568.0 million (Q4 2025), and $598.4 million (Q3 2025), per Business Quant data.